The influence of socioeconomic position on adjuvant treatment of stage III colon cancer: a systematic review and meta-analysis

References

• Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol. 2006;17(1):5–19.
   PubMed Web of Science ®Google Scholar
• Dalton SO, Olsen MH, Johansen C, et al. Socioeconomic inequality in cancer survival - changes over time. A population-based study, Denmark, 1987–2013. Acta Oncol. 2019;58(5):737–744.
   PubMed Web of Science ®Google Scholar
• Galobardes B, Shaw M, Lawlor DA, et al. Indicators of socioeconomic position (part 1). J Epidemiol Community Health. 2006;60(1):7–12.
   PubMed Web of Science ®Google Scholar
• Williams-Brennan L, Gastaldo D, Cole DC, Paszat L. Social determinants of health associated with cervical cancer screening among women living in developing countries: a scoping review. Arch Gynecol Obstet. 2012;286(6):1487–1505.
   PubMed Web of Science ®Google Scholar
• Gast A, Mathes T. Medication adherence influencing factors-an (updated) overview of systematic reviews. Syst Rev. 2019;8(1):112
   PubMed Web of Science ®Google Scholar
• Singer S, Roick J, Briest S, et al. Impact of socio-economic position on cancer stage at presentation: findings from a large hospital-based study in Germany. Int J Cancer. 2016;139(8):1696–1702.
   PubMed Web of Science ®Google Scholar
• Bayar B, Yilmaz KB, Akinci M, et al. An evaluation of treatment results of emergency versus elective surgery in colorectal cancer patients. UCD. 2016;32(1):11–17.
   Google Scholar
• Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66(4):337–350.
   PubMed Web of Science ®Google Scholar
• Aarts MJ, Lemmens VE, Louwman MW, et al. Socioeconomic status and changing inequalities in colorectal cancer? A review of the associations with risk, treatment and outcome. Eur J Cancer. 2010;46(15):2681–2695.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691.
   PubMed Web of Science ®Google Scholar
• Bertelsen CA, Neuenschwander AU, Jansen JE, et al. Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study. Lancet Oncol. 2015;16(2):161–168.,
   PubMed Web of Science ®Google Scholar
• Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol. 1989;7(10):1447–1456.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352–358.
   PubMed Web of Science ®Google Scholar
• Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol. 2004;22(10):1797–1806.
   PubMed Web of Science ®Google Scholar
• Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–2029.
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–3116.
   PubMed Web of Science ®Google Scholar
• Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768–3774.
   PubMed Web of Science ®Google Scholar
• Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–1471.
   PubMed Web of Science ®Google Scholar
• Etzioni DA, El-Khoueiry AB, Beart RW. Jr. Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer. 2008;113(12):3279–3289.
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.
   PubMed Web of Science ®Google Scholar
• Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol. 2007;36(3):666–676.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Cochrane book series. The Cochrane Collaboration. Wiley; 2008. p. 174–175.
   Google Scholar
• Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.0. Cochrane; 2019 [updated 2019 Jul]. Available from: www.training.cochrane.org/handbook
   Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Cochrane book series. The Cochrane Collaboration. 2008. p. 277–278.
   Google Scholar
• RStudio Team. 2015. RStudio: Integrated Development for R. Boston, MA: RStudio, Inc. Available from: http://www.rstudio.com
   Google Scholar
• VanEenwyk J, Campo JS, Ossiander EM. Socioeconomic and demographic disparities in treatment for carcinomas of the colon and rectum. Cancer. 2002;95(1):39–46.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Harlan LC, Warren JL, et al. Race and insurance differences in the receipt of adjuvant chemotherapy among patients with stage III colon cancer. J Clin Oncol. 2015;33(23):2530–2536.
   PubMed Web of Science ®Google Scholar
• Upadhyay S, Dahal S, Bhatt VR, et al. Chemotherapy use in stage III colon cancer: a National Cancer Database analysis. Ther Adv Med Oncol. 2015;7(5):244–251.
   PubMed Web of Science ®Google Scholar
• Hsieh MC, Thompson T, Wu XC, et al. The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients. Cancer Med. 2016;5(5):871–880.
   PubMed Web of Science ®Google Scholar
• Ortiz-Ortiz KJ, Tortolero-Luna G, Rios-Motta R, et al. Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: a population-based study. PLOS One. 2018;13(3):e0194415.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Tahseen A, England E, et al. Association between primary payer status and survival in patients with stage III colon cancer: an National Cancer Database Analysis. Clin Colorectal Cancer. 2019;18(1):e1–e7.
   PubMed Web of Science ®Google Scholar
• Gao P, Huang XZ, Song YX, et al. Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study. BMC Cancer. 2018;18(1):234.
   PubMed Web of Science ®Google Scholar
• Booth CM, Nanji S, Wei X, et al. Use and effectiveness of adjuvant chemotherapy for stage III colon cancer: a population-based study. J Natl Compr Canc Netw. 2016;14(1):47–56.
   PubMed Web of Science ®Google Scholar
• Panchal JM, Lairson DR, Chan W, et al. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer. Clin Colorectal Cancer. 2013;12(2):113–121.
   PubMed Web of Science ®Google Scholar
• Winget M, Hossain S, Yasui Y, et al. Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment. Cancer. 2010;116(20):4849–4856.
   PubMed Web of Science ®Google Scholar
• El Shayeb M, Scarfe A, Yasui Y, et al. Reasons physicians do not recommend and patients refuse adjuvant chemotherapy for stage III colon cancer: a population based chart review. BMC Res Notes. 2012; 5:269
   PubMedGoogle Scholar
• Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93(11):850–857.
   PubMed Web of Science ®Google Scholar
• Lemmens VE, van Halteren AH, Janssen-Heijnen ML, et al. Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity. Ann Oncol. 2005;16(5):767–772.
   PubMed Web of Science ®Google Scholar
• van Steenbergen LN, Rutten HJ, Creemers GJ, et al. Large age and hospital-dependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands. Ann Oncol. 2010;21(6):1273–1278.
   PubMed Web of Science ®Google Scholar
• Baldwin LM, Dobie SA, Billingsley K, et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst. 2005;97(16):1211–1220.
   PubMedGoogle Scholar
• Luo R, Giordano SH, Freeman JL, et al. Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer. Oncologist. 2006;11(9):1025–1033.
   PubMed Web of Science ®Google Scholar
• McGory ML, Zingmond DS, Sekeris E, et al. A patient's race/ethnicity does not explain the underuse of appropriate adjuvant therapy in colorectal cancer. Dis Colon Rectum. 2006; 49:319–329.
   PubMed Web of Science ®Google Scholar
• Sparling AS, Song E, Klepin HD, et al. Is distance to chemotherapy an obstacle to adjuvant care among the N.C. Medicaid-enrolled colon cancer patients?. J Gastrointest Oncol. 2016;7(3):336–344.
   PubMed Web of Science ®Google Scholar
• Cavalli-Bjorkman N, Lambe M, Eaker S, et al. Differences according to educational level in the management and survival of colorectal cancer in Sweden. Eur J Cancer. 2011;47(9):1398–1406.
   PubMed Web of Science ®Google Scholar
• Hershman D, Hall MJ, Wang X, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer. 2006;107(11):2581–2588.
   PubMed Web of Science ®Google Scholar
• Lima IS, Yasui Y, Scarfe A, et al. Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada. Cancer. 2011;117(16):3833–3840.
   PubMed Web of Science ®Google Scholar
• Merkow RP, Bentrem DJ, Mulcahy MF, et al. Effect of postoperative complications on adjuvant chemotherapy use for stage III colon cancer. Ann Surg. 2013; 258:847–853.
   PubMed Web of Science ®Google Scholar
• Massarweh NN, Haynes AB, Chiang YJ, et al. Adequacy of the National Quality Forum's Colon Cancer Adjuvant Chemotherapy Quality Metric: is 4 months soon enough?. Ann Surg. 2015;262(2):312–320.
   PubMed Web of Science ®Google Scholar
• van der Geest LG, Portielje JE, Wouters MW, et al. Complicated postoperative recovery increases omission, delay and discontinuation of adjuvant chemotherapy in patients with Stage III colon cancer. Colorectal Dis. 2013;15(10):e582–591.
   PubMed Web of Science ®Google Scholar
• Wu X, Chen VW, Andrews PA, et al. Treatment patterns for stage III colon cancer and factors related to receipt of postoperative chemotherapy in Louisiana. J La State Med Soc. 2004;156(5):255–261.
   PubMedGoogle Scholar
• Guerrero W, Wise A, Lim G, et al. Better Late than Never? Adherence to adjuvant therapy guidelines for stage III colon cancer in an underserved region. J Gastrointest Surg. 2018;22(1):138–145.
   PubMed Web of Science ®Google Scholar
• Sarasqueta C, Perales A, Escobar A, et al. Impact of age on the use of adjuvant treatments in patients undergoing surgery for colorectal cancer: patients with stage III colon or stage II/III rectal cancer. BMC Cancer. 2019;19(1):735.
   PubMed Web of Science ®Google Scholar
• Malietzis G, Mughal A, Currie AC, et al. factors implicated for delay of adjuvant chemotherapy in colorectal cancer: a meta-analysis of observational studies. Ann Surg Oncol. 2015;22(12):3793–3802.
   PubMed Web of Science ®Google Scholar
• Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi64–72.
   PubMed Web of Science ®Google Scholar
• Forrest LF, Adams J, Wareham H, et al. Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis. PLoS Med. 2013;10(2):e1001376.
   PubMed Web of Science ®Google Scholar
• Schrijvers CT, Coebergh JW, Mackenbach JP. Socioeconomic status and comorbidity among newly diagnosed cancer patients. Cancer. 1997;80(8):1482–1488.
   PubMed Web of Science ®Google Scholar
• Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. JCO. 2003;21(7):1293–1300.
   PubMed Web of Science ®Google Scholar
• Abbott DE, Voils CL, Fisher DA, et al. Socioeconomic disparities, financial toxicity, and opportunities for enhanced system efficiencies for patients with cancer. J Surg Oncol. 2017;115(3):250–256.
   PubMed Web of Science ®Google Scholar
• Galvin A, Delva F, Helmer C, et al. Sociodemographic, socioeconomic, and clinical determinants of survival in patients with cancer: a systematic review of the literature focused on the elderly. J Geriatr Oncol. 2018;9(1):6–14.
   PubMed Web of Science ®Google Scholar
• Verlinde E, De Laender N, De Maesschalck S, et al. The social gradient in doctor-patient communication. Int J Equity Health. 2012;11:12
   PubMed Web of Science ®Google Scholar
• Bernardo BM, Zhang X, Beverly Hery CM, et al. The efficacy and cost-effectiveness of patient navigation programs across the cancer continuum: a systematic review. Cancer. 2019;125(16):2747–2761.
   PubMed Web of Science ®Google Scholar
• Rosero ID, Ramirez-Velez R, Lucia A, et al. Systematic review and meta-analysis of randomized, controlled trials on preoperative physical exercise interventions in patients with non-small-cell lung cancer. Cancers (Basel). 2019;11(7):944.
   PubMed Web of Science ®Google Scholar
• Scheede-Bergdahl C, Minnella EM, Carli F. Multi-modal prehabilitation: addressing the why, when, what, how, who and where next?. Anaesthesia. 2019;74(Suppl 1):20–26.
   PubMed Web of Science ®Google Scholar
• Huston P, Naylor CD. Health services research: reporting on studies using secondary data sources. CMAJ. 1996;155(12):1697–1709.
   PubMed Web of Science ®Google Scholar
• Shavers VL. Measurement of socioeconomic status in health disparities research. J Natl Med Assoc. 2007;99(9):1013–1023.
   PubMed Web of Science ®Google Scholar
• Galobardes B, Lynch J, Smith GD. Measuring socioeconomic position in health research. Br Med Bull. 2007; 81-82:21–37.
   PubMed Web of Science ®Google Scholar